Drug Profile
C 6822
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals
- Developer Eli Lilly and Company; Takeda Oncology
- Class Ischaemic heart disorder therapies; Peptides
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Myocardial infarction; Stroke; Thrombosis; Unstable angina pectoris
Most Recent Events
- 12 Apr 1995 Discontinued-Preclinical for Myocardial infarction in USA (Unknown route)
- 12 Apr 1995 Discontinued-Preclinical for Stroke in USA (Unknown route)
- 12 Apr 1995 Discontinued-Preclinical for Thrombosis in USA (Unknown route)